Compare Ascendis Pharma A/S (ASND) vs Trump Media and Technology Group Corp (DJT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Trump Media and Technology Group Corp — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Trump Media and Technology Group Corp trades at $8.58 (market cap $2.37B). The key difference: Ascendis Pharma A/S is far larger — about 7.5× Trump Media and Technology Group Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| ASND | DJT | |
|---|---|---|
Market Cap | $17.74B | $2.37B |
Sector | Health | Media |
52-Week High | $277.18 | $19.86 |
52-Week Low | $163.32 | $7.06 |
Enterprise Value | $18.11B | $2.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DJT trades at $8.54, down 0.12% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported 2025 revenue of $3.68M but a net loss of -$712.06M, with a negative net income margin of -29,098.97%. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of plans to spin off Truth Social, while the merger with TAE Technologies remains pending.
The outlook is highly speculative with severe financial losses and minimal revenue growth, posing significant risks. Investment potential hinges on the TAE merger and Truth Social's expansion, but high volatility and negative profitability warrant extreme caution for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →
